Genistein reduces the activation of AKT and EGFR, and the production of IL6 in cholangiocarcinoma cells involving estrogen and estrogen receptors

Tanjak,Pariyada; Thiantanawat,Apinya; Watcharasit,Piyajit; Satayavivad,Jutamaad

doi:10.3892/ijo.2018.4375

Genistein reduces the activation of AKT and EGFR, and the production of IL6 in cholangiocarcinoma cells involving estrogen and estrogen receptors

Authors:
- Pariyada Tanjak
- Apinya Thiantanawat
- Piyajit Watcharasit
- Jutamaad Satayavivad
View Affiliations

Affiliations: Laboratory of Pharmacology, Chulabhorn Research Institute, Bangkok 10210, Thailand
Published online on: April 24, 2018 https://doi.org/10.3892/ijo.2018.4375
Pages: 177-188

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma (CCA) is a malignant tumor of the biliary epithelium associated with Opisthorchis viverrini, primary sclerosing cholangitis and hepatitis viral infection. In the global population, men have higher incidence rates for CCA than women; thus, a gender disparity in the progression of chronic inflammation of the biliary duct leading to malignancy may involve the effects of estrogen (E2). Genistein (GE), a prominent phytoestrogen found in soy products, is an estrogen receptor β (ERβ) agonist and a tyrosine kinase inhibitor. The present study investigated the effects of GE on the growth of CCA cells by cell viability assay. The effects on signaling proteins were detected by western blot analysis and ELISA. Gene expression was examined by RT-qPCR. Two human intrahepatic CCA cell lines, HuCCA‑1 and RMCCA‑1, were utilized. GE (50‑200 µM) reduced the viability of the two cell lines, and also inhibited the activation of epidermal growth factor receptor (EGFR) and AKT, as evidenced by decreasing protein levels of phosphorylated (p)-EGFR (Tyr1173) and p‑AKT (Ser473), respectively. GE altered the mitogen‑activated protein kinase signaling cascade by mediating decreased protein levels of p‑p38 and increased protein levels of p‑ERK1/2. GE significantly decreased the levels of interleukin 6 (IL6) and induced the expression of inducible nitric oxide synthase (iNOS). GE also downregulated the expression of p‑ERα (Ser118) protein and ERα mRNA levels. Finally, GE induced the downregulation of the protein levels of ERβ. Of note, E2 deprivation potentiated the GE-induced reduction of p‑EGFR (Tyr1173) and total AKT proteins and production of IL6, and mediated the downregulation of GE-induced iNOS protein. In conclusion, GE inhibited the growth of human CCA cell lines by reducing the activation of EGFR and AKT, and by attenuating the production of IL6. E2 and ER were also involved in the growth-inhibitory effect of GE in CCA cells.

View Figures

View References

1	Songserm N, Promthet S, Wiangnon S and Sithithaworn P: Prevalence and co-infection of intestinal parasites among thai rural residents at high-risk of developing cholangiocarcinoma: A cross-sectional study in a prospective cohort study. Asian Pac J Cancer Prev. 13:6175–6179. 2012. View Article : Google Scholar : PubMed/NCBI
2	Jaiswal M, LaRusso NF, Burgart LJ and Gores GJ: Inflammatory cytokines induce Dells by a nitric oxide-dependent mechanism. Cancer Res. 60:184–190. 2000.PubMed/NCBI
3	Sripa B, Thinkhamrop B, Mairiang E, Laha T, Kaewkes S, Sithithaworn P, Periago MV, Bhudhisawasdi V, Yonglitthipagon P, Mulvenna J, et al: Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini. PLoS Negl Trop Dis. 6:e16542012. View Article : Google Scholar : PubMed/NCBI
4	Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH and Gores GJ: Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology. 128:2054–2065. 2005. View Article : Google Scholar : PubMed/NCBI
5	Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD and Patel T: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology. 130:2113–2129. 2006. View Article : Google Scholar : PubMed/NCBI
6	Yothaisong S, Thanee M, Namwat N, Yongvanit P, Boonmars T, Puapairoj A and Loilome W: Opisthorchis viverrini infection activates the PI3K/AKT/PTEN and Wnt/β-catenin signaling pathways in a Cholangiocarcinogenesis model. Asian Pac J Cancer Prev. 15:10463–10468. 2014. View Article : Google Scholar
7	Ewald F, Nörz D, Grottke A, Hofmann BT, Nashan B and Jücker M: Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs. 32:1144–1154. 2014. View Article : Google Scholar : PubMed/NCBI
8	Yoon H, Min JK, Lee JW, Kim DG and Hong HJ: Acquisition of chemoresistance in intrahepatic cholangiocarcinoma cells by activation of AKT and extracellular signal-regulated kinase (ERK)1/2. Biochem Biophys Res Commun. 405:333–337. 2011. View Article : Google Scholar
9	Kamsa-ard S, Wiangnon S, Suwanrungruang K, Promthet S, Khuntikeo N, Kamsa-ard S and Mahaweerawat S: Trends in liver cancer incidence between 1985 and 2009, Khon Kaen, Thailand: Cholangiocarcinoma. Asian Pac J Cancer Prev. 12:2209–2213. 2011.
10	Alvaro D, Barbaro B, Franchitto A, Onori P, Glaser SS, Alpini G, Francis H, Marucci L, Sterpetti P, Ginanni-Corradini S, et al: Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol. 169:877–888. 2006. View Article : Google Scholar : PubMed/NCBI
11	Shao W and Brown M: Advances in estrogen receptor biology: Prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 6:39–52. 2004. View Article : Google Scholar :
12	Guo RX, Wei LH, Tu Z, Sun PM, Wang JL, Zhao D, Li XP and Tang JM: 17 β-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem Mol Biol. 99:9–18. 2006. View Article : Google Scholar : PubMed/NCBI
13	Nicholson RI, McClelland RA, Robertson JF and Gee JM: Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer. 6:373–387. 1999. View Article : Google Scholar : PubMed/NCBI
14	Osborne CK, Shou J, Massarweh S and Schiff R: Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 11:865s–870s. 2005.PubMed/NCBI
15	Mancino A, Mancino MG, Glaser SS, Alpini G, Bolognese A, Izzo L, Francis H, Onori P, Franchitto A, Ginanni-Corradini S, et al: Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis. 41:156–163. 2009. View Article : Google Scholar :
16	Hunsawong T, Singsuksawat E, In-chon N, Chawengrattanachot W, Thuwajit C, Sripa B, Paupairoj A, Chau-in S and Thuwajit P: Estrogen is increased in male cholangiocarcinoma patients' serum and stimulates invasion in cholangiocarcinoma cell lines in vitro. J Cancer Res Clin Oncol. 138:1311–1320. 2012. View Article : Google Scholar : PubMed/NCBI
17	Isse K, Specht SM, Lunz JG III, Kang LI, Mizuguchi Y and Demetris AJ: Estrogen stimulates female biliary epithelial cell interleukin-6 expression in mice and humans. Hepatology. 51:869–880. 2010. View Article : Google Scholar : PubMed/NCBI
18	Sakla MS, Shenouda NS, Ansell PJ, Macdonald RS and Lubahn DB: Genistein affects HER2 protein concentration, activation, and promoter regulation in BT-474 human breast cancer cells. Endocrine. 32:69–78. 2007. View Article : Google Scholar : PubMed/NCBI
19	Liu D, Yan L, Wang L, Tai W, Wang W and Yang C: Genistein enhances the effect of cisplatin on the inhibition of non-small cell lung cancer A549 cell growth in vitro and in vivo. Oncol Lett. 8:2806–2810. 2014. View Article : Google Scholar : PubMed/NCBI
20	Yu Z, Li W and Liu F: Inhibition of proliferation and induction of apoptosis by genistein in colon cancer HT-29 cells. Cancer Lett. 215:159–166. 2004. View Article : Google Scholar : PubMed/NCBI
21	Ji G, Zhang Y, Yang Q, Cheng S, Hao J, Zhao X and Jiang Z: Genistein suppresses LPS-induced inflammatory response through inhibiting NF-κB following AMP kinase activation in RAW 264.7 macrophages. PLoS One. 7:e531012012. View Article : Google Scholar
22	Verdrengh M, Jonsson IM, Holmdahl R and Tarkowski A: Genistein as an anti-inflammatory agent. Inflamm Res. 52:341–346. 2003. View Article : Google Scholar : PubMed/NCBI
23	Gong L, Li Y, Nedeljkovic-Kurepa A and Sarkar FH: Inactivation of NF-kappaB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene. 22:4702–4709. 2003. View Article : Google Scholar : PubMed/NCBI
24	Gossner G, Choi M, Tan L, Fogoros S, Griffith KA, Kuenker M and Liu JR: Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol Oncol. 105:23–30. 2007. View Article : Google Scholar : PubMed/NCBI
25	Sirisinha S, Tengchaisri T, Boonpucknavig S, Prempracha N, Ratanarapee S and Pausawasdi A: Establishment and charac-terization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer. Asian Pac J Allergy Immunol. 9:153–157. 1991.PubMed/NCBI
26	Rattanasinganchan P, Leelawat K, Treepongkaruna SA, Tocharoentanaphol C, Subwongcharoen S, Suthiphongchai T and Tohtong R: Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient. World J Gastroenterol. 12:6500–6506. 2006. View Article : Google Scholar : PubMed/NCBI
27	Milo GE, Malarkey WB, Powell JE, Blakeslee JR and Yohn DS: Effects of steroid hormones in fetal bovine serum on plating ang cloning of human cells in vitro. In Vitro. 12:23–30. 1976. View Article : Google Scholar : PubMed/NCBI
28	Wilson VS, Bobseine K and Gray LE Jr: Development and characterization of a cell line that stably expresses an estrogen-responsive luciferase reporter for the detection of estrogen receptor agonist and antagonists. Toxicol Sci. 81:69–77. 2004. View Article : Google Scholar : PubMed/NCBI
29	Nakareangrit W, Thiantanawat A, Visitnonthachai D, Watcharasit P and Satayavivad J: Sodium arsenite inhibited genomic estrogen signaling but induced pERα (Ser118) via MAPK pathway in breast cancer cells. Environ Toxicol. 31:1133–1146. 2016. View Article : Google Scholar
30	Qin J, Teng J, Zhu Z, Chen J and Huang WJ: Genistein induces activation of the mitochondrial apoptosis pathway by inhibiting phosphorylation of Akt in colorectal cancer cells. Pharm Biol. 54:74–79. 2016. View Article : Google Scholar
31	Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW and Gores GJ: Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol. 41:808–814. 2004. View Article : Google Scholar : PubMed/NCBI
32	Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M and Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 262:5592–5595. 1987.PubMed/NCBI
33	Tadlock L and Patel T: Involvement of p38 mitogen-activated protein kinase signaling in transformed growth of a cholangiocarcinoma cell line. Hepatology. 33:43–51. 2001. View Article : Google Scholar
34	Braconi C, Swenson E, Kogure T, Huang N and Patel T: Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma. PLoS One. 5:e151952010. View Article : Google Scholar : PubMed/NCBI
35	Fritz WA, Wang J, Eltoum IE and Lamartiniere CA: Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol. 186:89–99. 2002. View Article : Google Scholar : PubMed/NCBI
36	Haldosén LA, Zhao C and Dahlman-Wright K: Estrogen receptor β in breast cancer. Mol Cell Endocrinol. 382:665–672. 2014. View Article : Google Scholar
37	Razumilava N and Gores GJ: Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI
38	Traganos F, Ardelt B, Halko N, Bruno S and Darzynkiewicz Z: Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res. 52:6200–6208. 1992.PubMed/NCBI
39	Nakamura Y, Tsuji S and Tonogai Y: Determination of the levels of isoflavonoids in soybeans and soy-derived foods and estimation of isoflavonoids in the Japanese daily intake. J AOAC Int. 83:635–650. 2000.PubMed/NCBI
40	Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S and Tungpradubkul S: Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int. 9:32009. View Article : Google Scholar : PubMed/NCBI
41	Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, Hirohashi S and Shibata T: Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 98:418–425. 2008. View Article : Google Scholar
42	Yoshikawa D, Ojima H, Kokubu A, Ochiya T, Kasai S, Hirohashi S and Shibata T: Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. Br J Cancer. 100:1257–1266. 2009. View Article : Google Scholar : PubMed/NCBI
43	Jiang L, Jiang LS, Yan LN, Li FY, Wang W, Cheng NS and Wen TF: Effects of epidermal growth factor receptor inhibitor genistein on proliferative cholangitis in rats. J Surg Res. 162:59–67. 2010. View Article : Google Scholar
44	Uckun FM, Narla RK, Jun X, Zeren T, Venkatachalam T, Waddick KG, Rostostev A and Myers DE: Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. Clin Cancer Res. 4:901–912. 1998.PubMed/NCBI
45	Roberts PJ and Der CJ: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26:3291–3310. 2007. View Article : Google Scholar : PubMed/NCBI
46	Huang X, Chen S, Xu L, Liu Y, Deb DK, Platanias LC and Bergan RC: Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res. 65:3470–3478. 2005. View Article : Google Scholar : PubMed/NCBI
47	Wang X, Martindale JL and Holbrook NJ: Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 275:39435–39443. 2000. View Article : Google Scholar : PubMed/NCBI
48	Li Z, Li J, Mo B, Hu C, Liu H, Qi H, Wang X and Xu J: Genistein induces G2/M cell cycle arrest via stable activation of ERK1/2 pathway in MDA-MB-231 breast cancer cells. Cell Biol Toxicol. 24:401–409. 2008. View Article : Google Scholar : PubMed/NCBI
49	Bishnupuri KS, Luo Q, Murmu N, Houchen CW, Anant S and Dieckgraefe BK: Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology. 130:137–149. 2006. View Article : Google Scholar : PubMed/NCBI
50	Zhu XF, Liu ZC, Xie BF, Li ZM, Feng GK, Yang D and Zeng YX: EGFR tyrosine kinase inhibitor AG1478 inhibits cell proliferation and arrests cell cycle in nasopharyngeal carcinoma cells. Cancer Lett. 169:27–32. 2001. View Article : Google Scholar : PubMed/NCBI
51	Wei Z, Song X and Shaikh ZA: Cadmium promotes the proliferation of triple-negative breast cancer cells through EGFR-mediated cell cycle regulation. Toxicol Appl Pharmacol. 289:98–108. 2015. View Article : Google Scholar : PubMed/NCBI
52	Treekitkarnmongkol W and Suthiphongchai T: High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. World J Gastroenterol. 16:4047–4054. 2010. View Article : Google Scholar : PubMed/NCBI
53	Frampton G, Invernizzi P, Bernuzzi F, Pae HY, Quinn M, Horvat D, Galindo C, Huang L, McMillin M, Cooper B, et al: Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut. 61:268–277. 2012. View Article : Google Scholar
54	Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H and Schiff R: Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 96:926–935. 2004. View Article : Google Scholar : PubMed/NCBI
55	Levin ER: Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol. 17:309–317. 2003. View Article : Google Scholar : PubMed/NCBI
56	Marzioni M, Torrice A, Saccomanno S, Rychlicki C, Agostinelli L, Pierantonelli I, Rhönnstad P, Trozzi L, Apelqvist T, Gentile R, et al: An oestrogen receptor β-selective agonist exerts anti-neoplastic effects in experimental intrahepatic cholangiocarcinoma. Dig Liver Dis. 44:134–142. 2012. View Article : Google Scholar
57	Gores GJ: Cholangiocarcinoma: Current concepts and insights. Hepatology. 37:961–969. 2003. View Article : Google Scholar : PubMed/NCBI
58	Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM and Karin M: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 317:121–124. 2007. View Article : Google Scholar : PubMed/NCBI
59	Johnson C, Han Y, Hughart N, McCarra J, Alpini G and Meng F: Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer. 1:58–70. 2012.PubMed/NCBI
60	Park J, Tadlock L, Gores GJ and Patel T: Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology. 30:1128–1133. 1999. View Article : Google Scholar : PubMed/NCBI
61	Hämäläinen M, Nieminen R, Vuorela P, Heinonen M and Moilanen E: Anti-inflammatory effects of flavonoids: Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm. 2007:456732007. View Article : Google Scholar
62	Nakaya M, Tachibana H and Yamada K: Isoflavone genistein and daidzein up-regulate LPS-induced inducible nitric oxide synthase activity through estrogen receptor pathway in RAW264.7 cells. Biochem Pharmacol. 71:108–114. 2005. View Article : Google Scholar : PubMed/NCBI
63	Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B and Gustafsson JA: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology. 139:4252–4263. 1998. View Article : Google Scholar : PubMed/NCBI
64	Manas ES, Xu ZB, Unwalla RJ and Somers WS: Understanding the selectivity of genistein for human estrogen receptor-β using X-ray crystallography and computational methods. Structure. 12:2197–2207. 2004. View Article : Google Scholar : PubMed/NCBI